Real-world study confirms Leqembi therapy benefits

• An actual-world examine discovered that almost all sufferers receiving the anti-amyloid remedy Leqembi (lecanemab) remained clinically steady after 17 months, with 75.9% remaining on the identical stage and 6.6% enhancing by 1 illness stage, for an total 82.5% steady or improved.
• Medical stability was reported no matter intercourse, race, ethnicity, or APOE e4 genetic standing, suggesting constant real-world effectiveness throughout a various affected person inhabitants.
• Almost 87% of contributors continued Leqembi therapy, indicating that almost all sufferers remained on remedy in routine medical follow.
• Security was per earlier research, with adversarial occasions occurring in 12.3% of individuals, with most instances reported as gentle and asymptomatic, aligning with the drug’s established security profile from medical trials.

Whereas receiving therapy for Alzheimer’s, sustaining medical stability is a vital aim. It will possibly enable a person to protect cognitive operate, independence, and high quality of life for so long as potential.

The info have been introduced at AAIC 2026 however has not but undergone peer evaluation or been revealed in a scientific journal.

The drug producers Eisai and Biogen launched press statements highlighting findings from the LEADER (Lecanemab in Early Alzheimer’s Illness) examine, an ongoing retrospective evaluation evaluating how lecanemab performs in routine medical follow throughout a number of healthcare facilities in the USA.

As an antibody intravenous (IV) infusion remedy, Leqembi has Food and Drug Administration (FDA) approval for treating early Alzheimer’s illness. This included these dwelling with gentle cognitive impairment (MCI) or gentle dementia resulting from Alzheimer’s illness with elevated beta-amyloid within the mind

In July 2026, the FDA additionally accepted a supplemental Biologics License Utility (sBLA) for a as soon as‑weekly LEQEMBI IQLIK subcutaneous injection as an at-home beginning dose for early Alzheimer’s illness.

Not like randomized medical trials, which check therapies below fastidiously managed circumstances, the LEADER examine was a real-world examine analyzing outcomes in sufferers receiving therapy as a part of normal medical care.

The interim evaluation included 432 contributors who had acquired a minimum of 7 Leqembi infusions and had enough follow-up knowledge to evaluate adjustments in illness stage.

Researchers reported that therapy outcomes appeared broadly constant throughout intercourse, race, ethnicity, and APOE e4 genetic standing, a gene variant related to an elevated danger of Alzheimer’s illness.

In response to the examine investigators, 75.9% of sufferers remained clinically steady over the therapy interval, whereas an extra 6.6% improved by one illness stage.

Which means almost 83% of evaluable contributors have been both steady or confirmed enchancment after receiving Leqembi for a median of 17 months.

Dung Trinh, MD, an internist at MemorialCare Medical Group and Chief Medical Officer of Wholesome Mind Clinic in Irvine, CA, who was not concerned within the examine, advised Medical Information As we speak:

“An important takeaway is that lecanemab seems possible to ship and monitor in routine medical follow, with 75.9% of evaluable sufferers remaining in the identical broad illness stage and one other 6.6% shifting from gentle dementia to the MCI class after a median of roughly 17 months.”

“These findings are encouraging, however stability on this examine meant remaining throughout the identical broad medical stage, not essentially experiencing no cognitive or practical decline,” Trinh defined.

The investigators additionally discovered that just about 87% elected to proceed therapy, suggesting a excessive stage of therapy persistence in routine medical follow.

“Remaining in an earlier stage of Alzheimer’s illness for longer may be significant to sufferers and households as a result of it could protect independence, communication, participation in household life, and the flexibility to make choices and plans,” Trinh advised us.

“Nonetheless, the time period clinically steady needs to be interpreted fastidiously as a result of sufferers should decline throughout the MCI or mild-dementia stage with out progressing to the following class. The discovering is subsequently an encouraging real-world sign somewhat than a assure of particular person profit, and the sufferers who moved from gentle dementia to MCI shouldn’t be described as having skilled a treatment or reversal of Alzheimer’s illness,” he added.

The security profile reported within the examine was typically per earlier medical trials and the FDA-approved label.

Amyloid-related imaging abnormalities (ARIA) describe a identified facet impact of anti-amyloid therapies that may contain mind swelling or small areas of bleeding. This adversarial occasion occurred in 12.3% of contributors, however the investigators state that almost all instances have been asymptomatic and gentle.

The researchers additionally reported encouraging findings amongst those that transitioned to once-monthly intravenous (IV) upkeep dosing.

Of the 432 contributors, 155 transitioned to once-every-4-weeks IV upkeep remedy, the place 72.3% remained steady and eight.4% improved.

The CLARITY AD clinical trial beforehand demonstrated that lecanemab may sluggish cognitive decline in folks with early Alzheimer’s illness over 18 months in contrast with a placebo to assist set up the drug’s potential medical profit.

The brand new LEADER knowledge present proof that the therapy could also be equally efficient in on a regular basis medical settings, the place people are typically extra various and should have further well being circumstances which might be usually excluded from medical trials.

“CLARITY AD and LEADER present completely different however complementary types of proof,” Trinh famous.

“CLARITY AD provides randomized, placebo-controlled proof that lecanemab slows cognitive and practical decline on common, whereas LEADER supplies details about how therapy is being delivered in on a regular basis follow, together with therapy persistence, security monitoring, clinical-stage patterns, and the transition to upkeep remedy.”
— Dung Trinh, MD

“Randomized trials are the stronger supply for figuring out therapy efficacy, whereas real-world research assist clinicians perceive implementation and affected person expertise exterior the managed trial surroundings. LEADER subsequently enhances the CLARITY AD proof however doesn’t change it,” Trinh mentioned.

Actual-world proof can even assist clinicians higher perceive how therapies carry out in routine follow, together with affected person adherence, security monitoring, and longer-term outcomes.

Though the findings are encouraging, a number of examine limitations needs to be thought-about.

The LEADER examine is observational and retrospective somewhat than a randomized managed trial. As such, there isn’t any untreated comparability group. Due to this fact, it’s not potential to find out how a lot of the noticed illness stability is attributable on to the remedy.

“Clinicians ought to view the LEADER findings as supportive and hypothesis-generating somewhat than proof of a therapy impact. With out an untreated comparability group, it’s inconceivable to find out what number of comparable sufferers would have remained in the identical illness stage with out lecanemab.”
— Dung Trinh, MD

“The retrospective design, broad disease-stage classes, potential inconsistencies in medical data, and requirement that sufferers obtain a minimum of seven infusions might also introduce choice bias by excluding some sufferers who discontinued therapy earlier due to adversarial occasions, medical points, logistical obstacles, or private choice,” Trinh advised MNT.

“The outcomes are most helpful as proof about real-world feasibility, persistence, monitoring, and security,” he famous.

Moreover, illness development was assessed utilizing clinicians’ evaluations of illness stage somewhat than standardized cognitive end result measures alone. The outcomes additionally symbolize an interim evaluation, that means further follow-up could present a extra full image of long-term effectiveness and security.

The researchers plan to proceed following contributors within the LEADER examine to judge longer-term outcomes, together with therapy persistence, upkeep dosing methods, and the effectiveness of newer administration approaches, reminiscent of subcutaneous formulations presently below investigation.

As disease-modifying therapies for Alzheimer’s illness change into extra extensively accessible, real-world research like LEADER could assist clinicians perceive who advantages most from therapy and the way these therapies carry out in settings exterior medical trials.

Nonetheless, randomized managed trials stay the strongest type of proof for figuring out therapy efficacy, with observational research seen as complementary sources of data.

“The outcomes don’t basically change therapy eligibility or established security necessities, however they might give clinicians better confidence that lecanemab may be built-in into routine care when the required diagnostic, imaging, monitoring, and care-coordination programs are in place.”
— Dung Trinh, MD

“Selections ought to stay individualized and may think about affirmation of amyloid pathology, the expectation that therapy slows somewhat than stops decline, ARIA and hemorrhage dangers, APOE ε4 standing, MRI monitoring, anticoagulant or antithrombotic use, therapy burden, affected person objectives, and caregiver assist,” Trinh mentioned.

“The findings additionally reinforce the significance of a coordinated pathway that begins with main care recognition and analysis, makes use of blood-based biomarkers appropriately for triage, consists of specialist affirmation and treatment-readiness evaluation, and continues with shared follow-up between specialists and first care,” he concluded.